Bev, as an anti-VEGF agent, may thus induce immune response through several mechanisms including increased trafficking of T cells into tumors, reduction of suppressive cytokines and tumor-infiltrating T regulatory cells and MDSCs, increased CD8+ and CD4+ central memory T cells, and reduced frequency of MDSCs [31’34]. The gene discussed is CD8A; the disease is neoplasm.